Chanhaeng Rhee, MD
Endocrinology, Diabetes & Metabolism · Honolulu, HINPI 1649464280
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,068 and has fallen 87.1% since, to $138 in 2025.
Across 32 payments — averaging $53.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$370
- Tandem Diabetes Care, Inc.$257
- Insulet Corporation$256
- Bayer$250
- Novo Nordisk$144
- Corcept Therapeutics$133
- plus $312 from 8 others
What the payments were for
- Food & beverage$1,70699%
- Education$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 5 | $370 |
| Tandem Diabetes Care, Inc. | 4 | $257 |
| Insulet Corporation | 5 | $256 |
| Bayer | 2 | $250 |
| Novo Nordisk | 4 | $144 |
| Corcept Therapeutics | 2 | $133 |
| Kyowa Kirin, Inc. | 1 | $125 |
| AstraZeneca | 3 | $60 |
| Lilly USA, LLC | 1 | $26 |
| Dexcom, Inc. | 1 | $23 |
| Medtronic | 1 | $21 |
| Mannkind Corporation | 1 | $21 |
| Amryt Pharma Holdings Ltd | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,722 in reported general payments places this provider in the 60th percentile of 22 endocrinology, diabetes & metabolism providers in Hawaii.
See all endocrinology, diabetes & metabolism providers in Hawaii →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 142 | $171,447 |
| OzempicSemaglutide | 106 | $167,680 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 21 | $51,542 |
| ForteoTeriparatide | 11 | $45,978 |
| RybelsusSemaglutide | 19 | $43,097 |
| MounjaroTirzepatide | 14 | $43,034 |
| TrulicityDulaglutide | 19 | $31,975 |
| Novolog FlexpenInsulin Aspart | 80 | $25,644 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $20,299 |
| Humalog Kwikpen U-100Insulin Lispro | 49 | $19,417 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $14,256 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 91 | $13,760 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 93 | $11,361 |
| XyostedTestosterone Enanthate | 12 | $7,392 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 33 | $4,813 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $144 | $210,777125 claims |
| Lilly USA, LLCForteo, Mounjaro, Trulicity | $26 | $120,98744 claims |
| AmgenEvenity (2 Syringes) | $370 | $51,54221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 22 endocrinology, diabetes & metabolism providers in Hawaii.
Other endocrinology, diabetes & metabolism in Honolulu
- Alan ParsaHonolulu$584K
- Cindy PauHonolulu$13K
- Anna Melissa LoHonolulu$13K
- Lisa WongHonolulu$12K
- Eric LeeHonolulu$3K
- Isabel CasimiroHonolulu$2K
- Se Mo SuhHonolulu$2K
- Kamonkiat WirunsawanyaHonolulu$1K
- Jennifer LohHonolulu$890
- Lara WongHonolulu$399
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.